THE government of India has decided to cap trade margins on non-scheduled anti-cancer drugs at 30 per cent, according to the Indian Pharmaceutical Alliance (IPA).
As per the Indian Pharmaceutical Alliance (IPA), the announcement of trade margin rationalization for cancer medicines is a welcome step.
This is a balanced approach for patient welfare while assuring adequate margins to the channel members.
Lower drug prices could improve access to preoperative and postoperative systemic therapy, reduce treatment abandonment, and ease financial distress. The proposed price reductions of up to 70 per cent could provide meaningful relief and reduce out-of-pocket expenditure. — ANI